PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Parenteral anticoagulant
Drug: Warfarin
Drug: Apixaban
Drug: Rivaroxaban
Drug: Dabigatran
Drug: Edoxaban

First Posted Date: 2021-08-26

Last Posted Date: 2023-08-03

Lead Sponsor: Pfizer

Target Recruit Count: 55759

Registration Number: NCT05022563

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
🇰🇷
Sungkyunkwan University, Suwon-si, Korea, Republic of

COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States

Completed

Conditions: Breakthrough Infection
Covid-19
Immunosuppressed
SARS-COV-2 Infection
Immunocompromised
SARS-COV-2

Interventions: Biological: BNT162b2 (Tozinameran)

First Posted Date: 2021-08-25

Last Posted Date: 2024-02-12

Lead Sponsor: Pfizer

Target Recruit Count: 1277747

Registration Number: NCT05020145

Locations: 🇺🇸
Pfizer Inc., New York, New York, United States

MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Pomalidomide
Drug: Daratumumab
Drug: Dexamethasone

First Posted Date: 2021-08-25

Last Posted Date: 2024-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 761

Registration Number: NCT05020236

Locations: 🇺🇸
MSK Bergen, Montvale, New Jersey, United States
🇺🇸
MSK Commack, Commack, New York, United States
🇺🇸
MSK Westchester, Harrison, New York, United States

and more 258 locations

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab

First Posted Date: 2021-08-20

Last Posted Date: 2024-11-27

Lead Sponsor: Pfizer

Target Recruit Count: 86

Registration Number: NCT05014412

Locations: 🇺🇸
UF Health Shands Hospital Pharmacy Investigational Drug Service - Main, Gainesville, Florida, United States
🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States

and more 40 locations

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Palbociclib + aromatase inhibitor
Drug: Aromatase inhibitor

First Posted Date: 2021-08-19

Last Posted Date: 2024-10-07

Lead Sponsor: Pfizer

Target Recruit Count: 197

Registration Number: NCT05012644

Locations: 🇺🇸
Pfizer New York, New York, New York, United States

Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: avelumab
Drug: axitinib

First Posted Date: 2021-08-19

Last Posted Date: 2023-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT05012865

Locations: 🇯🇵
Osaka University Hospital, Suita-city, Osaka, Japan
🇯🇵
Jichi Medical University Saitama Medical Center, Saitama City, Saitama, Japan
🇯🇵
Kurume University Hospital, Kurume, Fukuoka, Japan

and more 9 locations

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: PF-07321332
Drug: Placebo
Drug: Ritonavir

First Posted Date: 2021-08-18

Last Posted Date: 2023-08-14

Lead Sponsor: Pfizer

Target Recruit Count: 1440

Registration Number: NCT05011513

Locations: 🇺🇸
Eastern Research Inc, Hialeah, Florida, United States
🇺🇸
Premium Medical Research Corp, Miami, Florida, United States
🇺🇸
South Florida Research Center, Inc., Miami, Florida, United States

and more 217 locations

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: PF-07321332
Drug: Ritonavir

First Posted Date: 2021-08-13

Last Posted Date: 2023-09-06

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT05005312

Locations: 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸
Orange County Research Center, Tustin, California, United States

A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma

Phase 2

Terminated

Conditions: Leiomyosarcoma

Interventions: Drug: Ontorpacept (TTI-621)
Drug: Doxorubicin

First Posted Date: 2021-08-09

Last Posted Date: 2024-12-11

Lead Sponsor: Pfizer

Target Recruit Count: 76

Registration Number: NCT04996004

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States

and more 19 locations

Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma

Phase 1

Terminated

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Zavegepant

First Posted Date: 2021-08-03

Last Posted Date: 2024-07-19

Lead Sponsor: Pfizer

Target Recruit Count: 45

Registration Number: NCT04987944

Locations: 🇨🇦
McMaster Universtiy, Hamilton, Ontario, Canada
🇨🇦
University of Saskatchewan/Royal University Hospital, Saskatoon, Saskatchewan, Canada
🇨🇦
McMaster University, Hamilton, Ontario, Canada

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy